Tick-Borne Encephalitis: The Viral Brain Infection Spreading Across Europe as Climate Change Extends Tick Season

KEY FACTS

• Approximately 10,000–12,000 clinical cases of tick-borne encephalitis are reported annually, though this figure significantly underestimates actual burden due to under-diagnosis and asymptomatic infections
• Up to 75% of tick-borne encephalitis virus infections remain asymptomatic, while 15% of symptomatic patients develop severe central nervous system disease during the second phase
• Case fatality rates range from 0.2% in Western Europe to 20% in Far Eastern Russia, depending on region and viral subtype, with post-encephalitic syndrome affecting up to 50% of survivors
• TBE vaccination shows 89–99% effectiveness across all age groups, preventing an estimated 1,000+ cases annually in Austria, Czech Republic, Latvia, Switzerland, and Sweden combined
• Switzerland’s TBE cases surged from 112 in 2014 to 436 in 2024, as climate change extended tick season from March to November and expanded suitable tick habitat from 16% to over 25% of the country

When a U.S. traveler returned home from a September 2022 hiking trip through Switzerland’s forested canton of Vaud, he carried more than memories of alpine scenery. Within days, fever and malaise progressed to devastating central nervous system involvement. Despite intensive care, the 74-year-old man died from tick-borne encephalitis—a viral brain infection he could have prevented with a three-dose vaccine series.

His death, reported in CDC’s November 2025 Emerging Infectious Diseases journal, underscores a troubling pattern: tick-borne encephalitis is no longer a disease confined to textbooks about obscure European pathogens. It’s expanding geographically, increasing in incidence, and claiming victims among both residents and travelers who don’t recognize the risks lurking in forests they assume are safe.

WHO has tracked this viral infection for decades as it evolved from a regional concern in Far Eastern Russia (where it was first described nearly a century ago) into what’s now recognized as the most important tick-borne viral disease across Eurasia. The virus exists in three main subtypes—European, Siberian, and Far Eastern—each carried by Ixodes ticks that are extending their range northward and to higher elevations as temperatures warm. With no specific antiviral treatment available, prevention through vaccination and tick avoidance remains the only protection against a disease that can leave survivors with permanent neurological damage.

This article examines WHO’s data on tick-borne encephalitis, investigates how climate change is reshaping transmission patterns, and asks whether current global health efforts can keep pace with a pathogen that’s literally moving across the map.

What Is Tick-Borne Encephalitis? — WHO’s Definition

According to WHO, tick-borne encephalitis is an infection of the central nervous system caused by tick-borne encephalitis virus (TBEV), a single-stranded RNA virus belonging to the genus Flavivirus within the Flaviviridae family. The virus exists primarily in three subtypes: the European subtype (most common in Central and Western Europe), the Siberian subtype (found in Russia and northern Asia), and the Far Eastern subtype (endemic in Far Eastern Russia, northern China, South Korea, and Japan).

WHO reports that TBEV is primarily transmitted to humans through bites from infected Ixodes species ticks—predominantly Ixodes ricinus in Europe and Ixodes persulcatus in Asia. The organization notes that transmission can occur remarkably quickly; laboratory experiments demonstrate the virus can transfer from an infected tick to a host within minutes of attachment, though transmission likelihood increases the longer a tick remains attached and feeding.

Beyond tick bites, WHO documents a less common but significant transmission route: consumption of unpasteurized milk and dairy products from infected but asymptomatic animals, particularly goats, sheep, and cattle. This alimentary transmission accounts for an estimated 1% of cases but can cause outbreaks when multiple people consume contaminated raw milk products.

The disease follows a characteristic biphasic pattern in symptomatic cases, WHO explains. After an incubation period lasting 2–28 days (most commonly 7–14 days), patients initially experience a viremic phase with general cold-like symptoms—fatigue, headache, malaise, and fever typically reaching 38°C or higher. This phase lasts 1–8 days before subsiding.

WHO identifies the critical second phase as occurring after an asymptomatic interval of 1–20 days. Up to 15% of infected individuals enter this phase, characterized by return of fever (often exceeding 40°C) and signs of central nervous system involvement: meningitis, encephalitis, myelitis, or radiculitis. The organization notes that this second phase can result in paralysis, permanent neurological sequelae, or death—with approximately 1% of neurologically affected patients dying, though rates reach significantly higher in Far Eastern Russia.

Global Burden — WHO’s Epidemiological Data

The global surveillance picture for tick-borne encephalitis reveals both dramatic underreporting and alarming expansion. WHO reports that approximately 10,000-12,000 clinical cases are documented annually from countries with mandatory reporting systems. But epidemiologists acknowledge this figure significantly underestimates true disease burden, given that up to 75% of infections remain asymptomatic and many endemic areas lack systematic surveillance.

European data provides the clearest epidemiological window. According to research published in PMC’s comprehensive TBE review, reported incidence rates rose from 0.4 to 0.9 cases per 100,000 people between 2015 and 2020—more than doubling in just five years. For 2020, TBE Book epidemiological analysis found that while 24 EU/EEA countries reported 3,817 cases to ECDC, country-specific chapter data summed to 5,429 cases, revealing substantial gaps even within Europe’s relatively robust surveillance systems.

The Baltic states and Central Europe bear the highest burden. Estonia, Latvia, Lithuania, Slovenia, and the Czech Republic regularly report some of Europe’s highest incidence rates. Research analyzing unvaccinated populations across Europe found incidence estimates ranging from 4.9 per 100,000 person-years in Switzerland to 8.9 in the Czech Republic among non-vaccinated individuals.

Regional hotspots show staggering concentration. In Finland’s municipality of Pargas, 2019 data revealed incidence of 53 per 100,000 inhabitants—more than 100 times the national average. Germany reports 80-90% of its cases from just two southern states: Baden-Württemberg and Bavaria. CDC’s January 2024 geographic risk assessment identifies Austria’s Tyrol and Vorarlberg regions with surveillance-reported incidence of 2.69 per 100,000, but seroprevalence surveys suggest actual infection rates reaching 610.1 per 100,000 among unvaccinated inhabitants annually.

Switzerland exemplifies the disease’s expansion trajectory. A fatal 2022 case reported in CDC’s Emerging Infectious Diseases noted that Swiss TBE cases jumped from 112 in 2014 to 436 in 2024—a nearly quadruple increase in one decade. Climate change has extended Switzerland’s tick season from the traditional April-October window to March-November, while suitable tick habitat expanded from approximately 16% of the country in 2009 to over 25% by recent estimates.

The virus isn’t limited to Europe. Japan, South Korea, and northern China report Far Eastern subtype cases, though systematic surveillance remains limited. Russia’s vast endemic areas span from its western borders through Siberia to the Pacific coast, but case numbers are difficult to verify given inconsistent reporting systems. Mongolia recently identified TBEV circulation, suggesting the endemic zone may be larger than currently mapped.

At-risk populations show distinct patterns. WHO notes that disease severity increases with age—mortality rates are highest among individuals over 60 years. Austrian surveillance data from 2000-2024 found that among 2,260 hospitalized TBE cases, 274 (12%) occurred in children ages 1-15, 1,066 (47%) in adults 16-59, and 920 (41%) in older adults over 60. Severe disease developed in 1,051 patients (47%), with 26 deaths (1.2% case fatality rate).

Occupational exposure creates heightened risk for forestry workers, agricultural laborers, military personnel, and outdoor recreation enthusiasts. The seasonal pattern aligns with peak tick activity—Central Europe sees most cases from April to November, with peaks in May and again in September-October corresponding to nymphal and adult tick feeding periods.

Long-term sequelae burden survivors substantially. Clinical research in PMC documents that post-encephalitic syndrome develops in up to 50% of patients after acute TBE, causing long-lasting morbidity affecting quality of life through persistent headaches, memory problems, balance disorders, and cognitive impairment that can endure for years or permanently. This mirrors the lasting impact seen in other neurological infections affecting vulnerable populations, similar to challenges documented in WHO’s 2024 progress report on Sustainable Development Goals targeting neurological disease burden reduction.

Causes, Transmission & Risk Factors — WHO’s Framework

WHO’s transmission framework identifies Ixodes ticks as the primary vectors maintaining TBEV in complex enzootic cycles involving small mammals—particularly rodents like bank voles, yellow-necked mice, and shrews—as reservoir hosts. Larger mammals including deer, roe deer, and wild boar may serve as “tick taxis,” supporting tick populations without necessarily maintaining viral circulation, though evidence suggests they can contribute to transmission dynamics.

The viral lifecycle operates through transstadial transmission, according to research published in PMC: ticks acquire TBEV by feeding on viremic reservoir animals. The virus persists as ticks molt from larvae to nymphs to adults, with each life stage capable of transmitting infection during subsequent blood meals. Co-feeding transmission represents a particularly efficient mechanism—uninfected ticks feeding near infected ticks on the same host can acquire virus even when the host itself isn’t viremic, bypassing traditional systemic infection requirements.

Tick saliva plays a critical immunomodulatory role. WHO documentation notes that tick salivary compounds suppress local immune responses at the bite site, facilitating viral establishment. This explains why transmission can occur within minutes to hours of tick attachment—far faster than the 24-48 hours typically required for other tick-borne pathogens like Lyme disease bacteria.

Environmental and ecological factors shape transmission intensity. Suitable habitat requires specific microclimatic conditions: adequate humidity for tick survival, mixed deciduous forests providing ground cover, and presence of reservoir host populations. Ecotones—transitional zones between forest and grassland—support particularly high tick densities. Human activities creating forest fragmentation and edge habitats may inadvertently increase encounter rates.

Climate change emerges as a major transmission amplifier across multiple pathways. Rising temperatures extend the active tick season, allow tick populations to establish at higher elevations and latitudes previously too cold for survival, and may increase viral replication rates within tick vectors. CDC’s geographic distribution analysis documents expanding endemic zones in countries like Finland, Sweden, Norway, and the Netherlands—all previously considered low-risk or TBE-free.

WHO identifies specific behavioral risk factors dramatically elevating human exposure. Outdoor activities in forested areas during peak tick season—hiking, camping, hunting, mushroom or berry picking, orienteering, mountain biking—all increase encounter probability. Occupational exposure affects forestry workers, farmers, military personnel conducting field exercises, and park maintenance staff. Even suburban and peri-urban green spaces in endemic areas pose risk, challenging assumptions that only remote wilderness harbors infected ticks.

Alimentary transmission through unpasteurized dairy products creates distinct epidemiological patterns. Outbreak investigations documented in scientific literature show that consuming raw goat or sheep milk/cheese from infected but asymptomatic animals can sicken multiple household or community members simultaneously. The virus concentration in milk varies, making risk unpredictable—not all products from infected animals transmit disease, complicating prevention messaging.

Individual susceptibility factors include lack of vaccination (the overwhelming determinant), age over 60 years (associated with more severe disease and worse outcomes), immunosuppression from medical conditions or medications, and possibly genetic factors influencing immune response. Interestingly, gender shows mixed patterns—some countries report higher incidence in males, possibly reflecting occupational or recreational exposure differences rather than biological susceptibility.

Signs, Symptoms or Health Impacts — WHO’s Clinical Framework

WHO identifies the classic biphasic presentation as occurring in approximately one-quarter to one-third of TBEV infections. The initial viremic phase begins 2-28 days after tick bite (average 7-14 days) with non-specific flu-like symptoms: fever reaching 38°C or higher, headache, myalgia, malaise, fatigue, and sometimes gastrointestinal complaints like nausea or vomiting. This phase typically lasts 1-8 days before resolving.

The organization notes that many patients consider themselves recovered at this point. But after an asymptomatic interval averaging 1-20 days, up to 15% enter the second neurological phase. Fever returns, often exceeding 40°C and accompanied by severe headache. Clinical manifestations depend on which central nervous system structures become inflamed.

WHO categorizes three main neurological presentations:

Meningitis (inflammation of meninges covering brain and spinal cord) produces severe headache, photophobia, neck stiffness, and meningeal signs on examination. This represents the mildest form of neuroinvasive disease and carries the best prognosis. Patients typically recover within weeks, though post-infectious fatigue may persist.

Encephalitis (brain inflammation) causes altered mental status, confusion, drowsiness, behavioral changes, and sensory disturbances. Seizures may occur. The organization reports that encephalitis severity varies widely—some patients experience mild confusion while others develop profound obtundation or coma. Permanent neurological deficits are common: memory impairment, concentration difficulties, personality changes, and movement disorders.

Meningoencephalomyelitis (involvement of meninges, brain, and spinal cord) represents the most severe form. WHO documents that spinal cord inflammation causes flaccid paralysis—typically affecting shoulders, arms, and respiratory muscles. Bulbar involvement affecting brainstem can impair swallowing, speech, and breathing. Respiratory muscle paralysis requiring mechanical ventilation signals critical disease with high mortality risk.

According to clinical research published in CDC’s Yellow Book, approximately three out of four TBEV infections remain completely asymptomatic. Among those developing symptoms, the proportion progressing to neuroinvasive disease varies by viral subtype: European subtype causes second-phase disease in 20-30% of symptomatic cases, while Far Eastern subtype may cause neurological involvement in up to 40% with higher mortality rates approaching 20-40%.

WHO emphasizes that disease severity correlates strongly with age. Children and adolescents typically experience milder illness—meningitis predominates, and full recovery is the norm. Adults ages 40-60 show intermediate severity. But individuals over 60 face substantially higher risks of severe encephalitis, prolonged hospitalization, permanent disability, and death. Austrian surveillance data confirms this pattern, with severe disease documented in 47% of hospitalized patients overall.

The post-encephalitic syndrome described by WHO affects 30-50% of neuroinvasive TBE survivors. Symptoms persist for months to years: chronic headaches, fatigue, memory and concentration problems, balance and coordination difficulties, mood disturbances including depression and irritability, sleep disorders, and reduced stress tolerance. These sequelae can profoundly impact work capacity, social functioning, and quality of life—yet they remain poorly understood and difficult to treat.

Rare clinical presentations exist. WHO notes an abortive form where illness resolves after the first viremic phase without neurological involvement. A chronic progressive form, almost exclusive to Siberian subtype infections, causes slowly worsening neurological deficits over months to years. Some patients develop movement disorders resembling Parkinson’s disease. Cognitive decline can mimic dementia.

Monophasic illness—where neurological symptoms begin immediately without a clear first viremic phase—associates with worse prognosis. The fatal 2022 U.S. traveler case exemplified this pattern, with death linked to older age, concurrent medical conditions, and monophasic presentation. Autopsy findings revealed extensive lymphocytic infiltration in brain tissue with neuronal loss—pathology consistent with severe TBE encephalitis.

Treatment or Health Response — WHO’s Current Approaches

WHO explicitly states that no specific antiviral therapy exists for tick-borne encephalitis. This fundamental limitation shapes all clinical management, which focuses entirely on supportive care and symptom control. According to the organization’s clinical guidance, treatment during the neurological phase requires hospitalization with intensive monitoring and intervention based on disease severity.

Supportive care forms the cornerstone of management. WHO reports that mild cases with meningitis alone may require only analgesics for headache, antipyretics for fever, antiemetics for nausea, and intravenous fluids for hydration. These patients typically recover within 1-2 weeks with symptomatic management alone.

Moderate to severe encephalitis or meningoencephalomyelitis demands intensive care unit admission. WHO documents that maintaining adequate oxygenation and ventilation becomes critical—respiratory muscle paralysis or brainstem involvement may necessitate mechanical ventilation for days to weeks. Intracranial pressure monitoring helps detect and manage cerebral edema before it causes herniation and death.

Seizure management requires anticonvulsant medications. WHO notes that controlling seizures proves essential both for patient safety and to prevent additional brain injury from prolonged epileptic activity. Some patients require ongoing anticonvulsants for months or indefinitely if post-infectious epilepsy develops.

The organization acknowledges significant controversy surrounding corticosteroid use. Some clinicians administer dexamethasone or methylprednisolone attempting to reduce inflammatory brain injury, though WHO notes that no high-quality evidence supports this practice. Clinical trials have failed to demonstrate benefit, and theoretical concerns exist that immunosuppression might prolong viral replication or worsen outcomes.

Rehabilitation represents a crucial but often overlooked treatment component. Clinical literature from PMC emphasizes that patients surviving severe TBE often require extensive physical therapy for motor deficits, occupational therapy for activities of daily living, speech therapy for bulbar dysfunction, and neuropsychological rehabilitation for cognitive impairment. Recovery trajectories vary enormously—some patients regain full function within months while others plateau with permanent disability.

Access to advanced supportive care creates stark geographic disparities in outcomes. High-income European countries with ICU availability, mechanical ventilation capacity, and rehabilitation services report case fatality rates of 0.2-2%. Middle-income endemic countries may see 5-10% mortality. But in resource-limited settings lacking intensive care infrastructure, mortality approaches or exceeds 20%—particularly for Far Eastern subtype infections requiring prolonged ventilatory support.

WHO’s framework on health system strengthening notes that even within endemic European countries, rural areas may lack neurological intensive care capacity, forcing long-distance transfers that delay treatment. Language barriers, incomplete vaccination records for travelers, and clinician unfamiliarity with TBE in non-endemic regions can all cause diagnostic delays and suboptimal management.

Prevention of TBE exposure during the initial tick bite remains vastly preferable to treating established disease. But WHO acknowledges a troubling reality: post-exposure prophylaxis doesn’t exist. Unlike rabies (where post-exposure vaccination prevents disease) or some bacterial tick-borne infections (treatable with prophylactic antibiotics), nothing can stop TBE progression once transmission occurs. This makes pre-exposure vaccination the only truly effective intervention for those traveling to or residing in endemic areas.

Prevention & WHO Strategies — Public Health Framework

WHO’s prevention framework centers on vaccination as the most effective protection against tick-borne encephalitis. The organization reports that four widely used vaccines of assured quality currently exist: FSME-Immun and Encepur (manufactured in Austria and Germany respectively, based on European virus strains), and TBE-Moscow and EnceVir (manufactured in Russia, based on Far Eastern strains).

According to WHO’s position paper on TBE vaccines, all four demonstrate safety and effectiveness, with clinical trial and post-licensure surveillance data showing 87-99% efficacy in preventing disease. Research published in the International Journal of Infectious Diseases analyzing European vaccine effectiveness studies from 2003-2023 found that TBE vaccines showed >92% effectiveness against TBEV infection across all age groups, with protection extending to mild infections and severe outcomes requiring prolonged hospitalization.

WHO recommends that vaccination should be offered to all inhabitants of regions with “prevaccination incidence” of TBE cases ≥5 per 100,000 population per year. For endemic areas, the organization supports routine childhood vaccination programs and catch-up vaccination for unprotected adults. Austria has implemented this recommendation most comprehensively, achieving Europe’s highest vaccination coverage—though recent data show declining adherence threatening to reverse gains.

The standard vaccination schedule requires three doses for primary immunization. CDC guidance on the TICOVAC vaccine (approved in the United States in 2021) specifies that adults ages 16 and older receive the first two doses 14 days to 3 months apart, with the third dose 5-12 months after the second. Children ages 1-15 receive the first two doses 1-3 months apart, followed by the third dose 5-12 months later. Accelerated schedules exist for travelers needing rapid protection.

WHO emphasizes that booster doses maintain immunity. The organization initially recommended boosters every 3-5 years, but recent research published in PMC found that protection wanes faster in older adults—suggesting boosters every 3 years for those over 60 rather than the conventional 5-year interval for younger adults. Antibody levels decline more rapidly with age, explaining higher breakthrough infection rates in elderly vaccinated populations.

Beyond vaccination, WHO promotes tick bite prevention as an essential complementary strategy. The organization recommends wearing long trousers tucked into socks, long-sleeved shirts, and closed footwear when hiking or working in forested areas. Light-colored clothing makes ticks easier to spot. Permethrin-treated clothing provides additional protection.

WHO advises thorough full-body tick checks after potential exposure, with prompt removal of attached ticks using fine-tipped tweezers to grasp the tick as close to the skin as possible. The organization notes that while rapid removal may reduce transmission risk for some tick-borne diseases, TBEV can transmit within minutes, making prevention of attachment more critical than removal speed for TBE specifically.

Avoiding unpasteurized dairy products in endemic areas represents WHO’s third prevention pillar. The organization recommends that travelers and residents consume only pasteurized milk, cheese, and other dairy products—particularly from goats and sheep. Heat treatment effectively inactivates TBEV, eliminating alimentary transmission risk.

Environmental management strategies receive less WHO emphasis, given TBEV’s complex enzootic cycle and the impossibility of eliminating wild reservoir hosts or tick populations across vast forested landscapes. Some endemic areas implement targeted tick control through acaricide application in high-use recreational areas, though effectiveness remains limited and environmental concerns exist about broad pesticide use.

Public education campaigns promoted by WHO and national health authorities focus on raising awareness of TBE risk in endemic and expanding endemic zones. Many residents in newly affected areas don’t recognize the threat, having never encountered TBE previously. Travelers from non-endemic countries often underestimate risk, viewing European destinations as “safe” and not requiring travel medicine consultation.

WHO’s Global Efforts — Recent Initiatives and Editorial Analysis

WHO’s engagement with tick-borne encephalitis dates back decades, but the organization’s strategic positioning has evolved as the disease burden has grown and geographic expansion has accelerated. The organization published its first position paper on TBE vaccines in November 2019, acknowledging TBE vaccination’s inclusion on WHO’s List of Essential Medicines—the safest and most effective medicines needed in a health system.

That 2019 position paper represented WHO’s first comprehensive technical guidance specifically on TBE immunization. The Strategic Advisory Group of Experts on Immunization (SAGE) reviewed evidence on vaccine efficacy, safety, immunogenicity across age groups, and public health value. SAGE’s recommendations established the ≥5 per 100,000 incidence threshold for population-based vaccination programs—a metric that’s now exceeded in numerous European endemic areas.

But here’s what’s striking about WHO’s TBE efforts: they’re almost entirely focused on vaccination policy rather than broader surveillance, outbreak response, or elimination goals. Unlike diseases where WHO has launched ambitious elimination initiatives or set specific reduction targets, TBE receives relatively minimal attention at the global health architecture level.

Why this limited engagement? The disease burden concentrates in middle- and high-income European countries with robust health systems capable of managing TBE independently. Unlike neglected tropical diseases disproportionately affecting low-income nations, TBE predominantly strikes populations with resources to develop and deploy vaccines, conduct surveillance, and provide intensive care for severe cases. WHO’s mandate prioritizes conditions where international coordination and resource mobilization prove essential—TBE doesn’t fit that profile.

Recent developments suggest this calculus may need revisiting. Climate change is fundamentally altering TBE epidemiology. Swiss federal surveillance data documenting the quadrupling of cases from 2014 to 2024 illustrates what’s happening across Europe: warming temperatures, extended tick seasons, expanding habitat suitability, and virus establishment in previously non-endemic areas. Finland, Sweden, the Netherlands, and parts of the United Kingdom are all detecting TBE or suitable conditions for transmission where the disease was historically absent.

This expansion creates multiple challenges WHO hasn’t adequately addressed. First, populations in newly endemic areas lack immunity—natural or vaccine-induced. When TBE enters virgin populations, infection rates can surge before public health responses activate. Second, healthcare providers in expanding endemic zones often don’t consider TBE in differential diagnoses, causing delays in recognition and treatment. Third, vaccine uptake remains poor even in long-endemic areas where awareness should be highest.

Austrian data from 2000-2024 reveals a troubling paradox: despite having Europe’s highest TBE vaccination coverage, Austria documented declining vaccine uptake and adherence over time, coinciding with significantly rising case numbers in unvaccinated and irregularly vaccinated populations. TBE vaccination prevented more than 10,000 hospitalizations, 4,000 severe cases, and 80 deaths between 2000-2024 in Austria alone. Yet vaccine-preventable cases continue mounting as coverage erodes.

Sweden’s experience mirrors this. Research published in Scientific Reports analyzing 2018-2022 data found that despite vaccine effectiveness of 89% against TBE, only 48% of the population in endemic areas had received three doses. The study estimated that vaccination averted approximately 1,000 TBE cases over five years—but that receipt of three doses by the entire Swedish population would have prevented 2,688 cases, suggesting two-thirds of potential protection remains unrealized.

What explains this vaccination gap? Cost represents one barrier—TBE vaccines aren’t universally covered by public health systems, particularly for travelers. A three-dose series can cost €100-200 out-of-pocket in many countries. Awareness remains insufficient; people don’t perceive personal risk even in endemic areas. Vaccine hesitancy affects uptake, with some individuals questioning necessity for a “rare” disease. Schedule complexity—requiring three doses over months—creates dropout between doses.

WHO’s 2019 position paper acknowledged these challenges but offered limited solutions beyond the ≥5 per 100,000 incidence threshold recommendation. The organization hasn’t launched campaigns to increase awareness in endemic or expanding endemic areas. It hasn’t worked with vaccine manufacturers to improve affordability or access. It hasn’t developed standardized protocols for newly endemic countries to implement vaccination programs. These gaps reflect WHO’s constrained resources and competing priorities, but they leave significant public health needs unmet.

International coordination on TBE surveillance reveals similar shortcomings. The TBE Book’s epidemiology chapter notes that European surveillance remains “more sporadic than systematic,” with TBE cases likely underreported across the continent. No standardized case definitions exist globally. Reporting requirements vary by country. Cross-border data sharing happens through voluntary networks rather than formal WHO mechanisms. This fragmented surveillance makes assessing true disease burden, tracking geographic expansion, or evaluating intervention impacts difficult.

The organization’s limited engagement also means missed opportunities for research prioritization. Critical knowledge gaps persist: optimal booster intervals for older adults, correlates of protection beyond antibody titers, effectiveness of accelerated vaccination schedules, duration of protection after natural infection, and clinical management strategies to improve outcomes. WHO could coordinate multi-country research agendas addressing these questions, but TBE doesn’t feature prominently in the organization’s research priorities.

Perhaps WHO’s most significant TBE contribution has been maintaining vaccines on the Essential Medicines List, legitimizing their public health importance and potentially facilitating access in low- and middle-income countries if they become endemic. But even this feels reactive rather than strategic—placing vaccines on a list doesn’t drive uptake or ensure availability.

What should WHO do differently? First, establish active surveillance coordination across endemic and newly endemic countries, with standardized definitions and reporting mechanisms. Second, develop technical guidance for countries facing recent TBE emergence—how to conduct risk assessments, implement vaccination programs, educate healthcare providers, and communicate risk to populations. Third, convene manufacturers and funders to address vaccine affordability and access barriers. Fourth, commission systematic reviews on outstanding research questions and coordinate studies to fill evidence gaps.

The organization might also consider whether TBE warrants disease-specific reduction targets, even if not elimination. Setting goals like reducing neuroinvasive TBE cases by X% by 2030, achieving Y% vaccination coverage in high-incidence areas, or establishing surveillance in all known endemic countries would focus attention and mobilize resources. The absence of such targets suggests WHO views TBE as a problem for affected countries to manage individually rather than a global health priority requiring coordinated action.

But perhaps that assessment made sense when TBE was confined to well-demarcated endemic foci. With climate change driving geographic expansion, increasing case numbers even in highly vaccinated populations, and evidence that current responses aren’t adequately protecting vulnerable populations, maybe it’s time for WHO to reconsider whether TBE deserves more strategic engagement.

The virus certainly isn’t waiting for bureaucratic processes to evolve. It’s expanding its range, finding new hosts, and claiming victims who don’t know they’re at risk. Whether WHO steps up with more comprehensive technical leadership or leaves endemic countries to address these challenges independently will shape how many more travelers—and residents—suffer the devastating neurological consequences of an eminently preventable disease.

Frequently Asked Questions

---

Sources

1. World Health Organization. Tick-borne encephalitis health topic page. November 6, 2019. https://www.who.int/health-topics/tick-borne-encephalitis/
2. Centers for Disease Control and Prevention. Tick-borne Encephalitis Vaccine. CDC Yellow Book 2026. November 17, 2025. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/tick-borne-encephalitis.html
3. Pustijanac E, Buršić M, Talapko J, et al. Tick-Borne Encephalitis Virus: A Comprehensive Review of Transmission, Pathogenesis, Epidemiology, Clinical Manifestations, Diagnosis, and Prevention. Microorganisms. 2023;11:1634. https://pmc.ncbi.nlm.nih.gov/articles/PMC10383662/
4. Erber W, Broeker M, Dobler G, Chitimia-Dobler L, Schmitt HJ. Chapter 12: Epidemiology of TBE. The TBE Book. April 30, 2025. https://tbenews.com/tbe/chapter-12-epidemiology-of-tbe/
5. Aberle JH, Kundi M. Fatal Tick-Borne Encephalitis in Unvaccinated Traveler from the United States to Switzerland, 2022. Emerging Infectious Diseases. November 2025;31(11). https://wwwnc.cdc.gov/eid/article/31/11/25-1320_article

---

DISCLAIMER

This article adapts publicly available information from WHO’s Tick-borne Encephalitis page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider.

---

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn